SCHEMBL129899

SCHEMBL129899

[CH2]CC(C)OC(=O)CCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
LMNA P02545 4/20 0.44
MAPT P10636 2/20 0.37
MAPK1 P28482 1/20 0.37
FAAH O00519 4/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
ALOX15 P16050 1/20 0.34
FFAR3 O14843 2/20 0.33
HDAC3 O15379 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC8 Q9BY41 2/20 0.33
BCL9 O00512 1/20 0.33
CTNNB1 P35222 1/20 0.33
PRKCA P17252 1/20 0.33
PRKCE Q02156 1/20 0.33
PRKCQ Q04759 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20581736 1.00 ALDH1A1 (0.46) ALDH1A1LMNAMAPTMAPK1FAAH
SCHEMBL15392446 0.84 LMNA (0.67) ALDH1A1LMNAMAPTMAPK1PRKCA
SCHEMBL2989645 0.82 ALDH1A1 (0.50) ALDH1A1LMNAMAPTMAPK1FAAH
SCHEMBL130715 0.82
SCHEMBL1585214 0.82 ALDH1A1 (0.50) ALDH1A1LMNAMAPTMAPK1FAAH
SCHEMBL2980900 0.82 ALDH1A1 (0.50) ALDH1A1LMNAMAPTMAPK1FAAH
SCHEMBL1245755 0.80 ALDH1A1 (0.48) ALDH1A1LMNAMAPTMAPK1FAAH
SCHEMBL9628763 0.80 ALDH1A1 (0.48) ALDH1A1LMNAMAPTMAPK1FAAH
SCHEMBL8044869 0.80 ALDH1A1 (0.48) ALDH1A1LMNAMAPTMAPK1FAAH
SCHEMBL9447620 0.80 ALDH1A1 (0.48) ALDH1A1LMNAMAPTMAPK1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12006311-B2 Compounds for use in preventing or treating cancer FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) 2024-06-11 US disclosed
WO-2024083861-A1 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF SELABTEC SCIENCES, SLU (ES) 2024-04-25 WO disclosed
EP-4356909-A1 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF Selabtec Sciences, SLU (ES) 2024-04-24 EP disclosed
EP-3271468-B1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) 2022-12-14 EP disclosed
CN-107849594-B Deamination of organophosphorus nucleosides 科技学专业学院有限公司 2022-01-18 CN disclosed
US-20210230150-A1 COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER AMIRA THERAPEUTICS, S.L. (ES) 2021-07-29 US disclosed
EP-3813832-A1 COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) 2021-05-05 EP disclosed
US-20180066295-A1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION, S.L.U. (ES) 2018-03-08 US disclosed
EP-3271468-A1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES Institut Univ. de Ciència i Tecnologia, S.A. (ES) 2018-01-24 EP disclosed
EP-3128013-A1 DEAMINATION OF ORGANOPHOSPHOROUS-NUCLEOSIDES Institut Univ. de Ciència i Tecnologia, S.A. (ES) 2017-02-08 EP disclosed
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 US disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 EP disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP disclosed
US-5843951-A Analgesic composition of pyrazolo(1,5-A) pyrimidines OTSUKA PHARMACEUTICAL FACTORY INC. (JP) 1998-12-01 US disclosed
EP-0795555-A1 ANALGESICS OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1997-09-17 EP disclosed
US-4818429-A FERROELECTRIC LIQUID CRYSTAL DISPLAY ELEMENTS; GOOD RESPONSE CHISSO CORPORATION (JP) 1989-04-04 US disclosed
EP-0260153-A2 Cyclohexylphenylpyridazines Chisso Corporation (JP) 1988-03-16 EP disclosed
US-4398913-A ALKALINE PASTES CASSELLA AKTIENGESELLSCHAFT (DE) 1983-08-16 US disclosed
US-4386935-A Process for producing discharge reserve prints on textile materials with amino-azo-benzene dyes CASSELLA AKTIENGESELLSCHAFT (DE) 1983-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 ALDH1A1 580/4885LMNA 1679/4885MAPT 4877/4885
US-20210230150-A1 COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER UGT1A3, UGT1A1, UGT1A6 ALDH1A1 14/4885LMNA 1451/4885MAPT 2700/4885
US-12006311-B2 Compounds for use in preventing or treating cancer UGT1A3, UGT1A1, UGT1A6 ALDH1A1 14/4885LMNA 1451/4885MAPT 2700/4885
US-20180066295-A1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES ADA, CDA, DCTD ALDH1A1 816/4885LMNA 3127/4885MAPT 4631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.